Six Month Clinical Outcomes of SMT’s Supralimus-Sirolimus Eluting Stent is Presented at EuroPCR 09

Surat, Gujarat -- (SBWire) -- 07/06/2009 -- Six months outcome of Sahajanand Medical Technologies Supralimus-Sirolimus Eluting stent with Bioabsorbable Polymer was presented at EuroPCR 2009. This analysis was performed as a part of the prospective of E-Series Multicenter Registry. The dataset demonstrates excellent results in high risk patients with complex coronary lesions, including high procedural success rate (> 97%), and sustained safety.

Presented by Dr. Ricardo A. Costa, of Cardiovascular Research Center, Brazil, Preliminary clinical results at 6 months (60%) from Multicenter E-Series Registry demonstrate clinical effectiveness of Supralimus in preventing revascularization, with only 2% TVR (Target Vessel Revascularization) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patient’s in-Hospital. The stent thrombosis rate (definite/probable, ARC) up to 6 months was less than 1%.

Out-of Hospital adverse events (N=718) included only 2% Cardiac Death, 0.5% MI (Myocardial infarction) and 4.5% of MACE (Major Cardiac Adverse Event). Thus the preliminary data with the Supralimus-Sirolimus Eluting Stent has shown promising results.

The Study was conducted by Dr. Alexandre Abizaid, Dr. Ricardo Costa and others from Jan 2007 which involved 1181 Patients with 1260 lesions and prospectively enrolled in 50 cities of Brazil, Venezuela and India. The included patients were real world scenario with routine or emergency PCI. Mean age of patients was 64 years & risk factors included 79% Hypertension, 38% Diabetes, 31% Smoker, 23% with Previous MI, 64% with Dyslipidemia, 34% with Previous PCI and 46% with Family History of CAD. Clinical follow was scheduled at 1, 6, 12 and 24 months. Final analysis of this registry is awaited with great hope & promise.